ResearcherUniversity of CataniaActive in the last 2 years

Ferdinando Nicoletti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4570-8462; OpenAlex author ID A5105878418. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 1 paper

Papers 2

Transcriptomic and Clinical Profiling Reveals LGALS3 as a Prognostic Oncogene in Pancreatic Cancer. Last author DOI 10.3390/genes16101170 ↗
The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic cancer via the CARD9-BCL10-MALT1 / NF-κB … Co-author DOI 10.1016/j.clim.2022.109217 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Grazia Scuderi · 1 shared paper, 2025 · strength 0.25
- Paper Transcriptomic and Clinical Profiling Reveals LGALS3 as a Prognostic Oncogene in Pancreatic Cancer. DOI 10.3390/genes16101170 ↗
Senlin Li · 1 shared paper, 2023 · strength 0.18
- Paper The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic c… DOI 10.1016/j.clim.2022.109217 ↗
Qing Li · 1 shared paper, 2023 · strength 0.18
- Paper The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic c… DOI 10.1016/j.clim.2022.109217 ↗
Cheng Tian · 1 shared paper, 2023 · strength 0.18
- Paper The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic c… DOI 10.1016/j.clim.2022.109217 ↗
Ming Xiang · 1 shared paper, 2023 · strength 0.18
- Paper The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic c… DOI 10.1016/j.clim.2022.109217 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.